SecBot SecBot
8-K ·Filed Jul 29, 2026

BSX

BOSTON SCIENTIFIC CORP
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000885725-26-000051
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The sharp guidance reduction for both Q3 and full-year 2026, combined with the recently announced $700M-$800M restructuring plan, signals a material growth deceleration and cost pressures. Traders should watch for further downside risk if Q3 guidance proves optimistic given the macro and tariff headwinds cited. The $1.5B MiRus investment and $2B buyback provide some offset but do not reverse the fundamental slowdown.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$46.04
T+0 close · Jul 29, 2026 · via day close
Latest settled
−0.07%
T+60 · $46.01
Vs SPY
−4.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $46.04entry
  2. T+1 · 4mo ago −0.09%α −1.76% · $46.00
  3. T+5 · 3mo ago +3.69%α −1.84% · $47.74
  4. T+20 · 3mo ago +4.63%α −0.39% · $48.17
  5. T+60 · 26d ago −0.07%α −4.79% · $46.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Boston Scientific reported Q2 2026 adjusted EPS of $0.86, beating the $0.83 consensus by 3.6%, on revenue of $5.442B (7.5% reported growth, above the 5.5-7.5% guidance range). However, the company significantly lowered full-year 2026 guidance: organic revenue growth cut to 5-6% (from prior 6.5-8%) and adjusted EPS guidance reduced to $3.28-$3.32 (from $3.34-$3.41). The beat was overshadowed by the guidance cut and a 2-day-old restructuring plan (Item 2.05) with $700M-$800M in charges, signaling a material deceleration in the core business.

Key Financial Metrics

EPS
$0.86
est $0.83 · +3.6%
Revenue
$5.4B
est $5.4B · +1.3% · +7.5% YoY
Rating
miss
Guidance
Q3: 3-5% organic growth; FY: 5-6% organic growth
lowered

Key Facts

  • Q2 2026 adjusted EPS of $0.86 beat consensus of $0.83 by 3.6%
  • Q2 revenue of $5.442B grew 7.5% reported, at the high end of 5.5-7.5% guidance
  • Full-year 2026 organic revenue growth guidance slashed to 5-6% from prior 6.5-8%
  • Full-year 2026 adjusted EPS guidance lowered to $3.28-$3.32 from $3.34-$3.41
  • Q3 2026 organic revenue growth guided to just 3-5%, a sharp deceleration
  • Completed $2B accelerated share repurchase, repurchasing ~40M shares
  • Invested $1.5B for ~34% equity stake in MiRus LLC with option to acquire TAVR business
  • Restructuring plan (filed 2 days ago) carries $700M-$800M in pre-tax charges through 2029

Financial Impact

Full-year revenue growth guidance cut by ~150-200bps; EPS guidance cut by $0.06-$0.09 per share

revenueepsguidance

Risk Factors

  • Further revenue deceleration in H2 2026 if Q3 guidance proves too optimistic
  • Restructuring execution risk and potential for additional charges
  • Tariff and geopolitical headwinds impacting international operations
  • Integration risk from MiRus investment and potential future acquisition

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
79% bullish (39 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000885725-26-000051
Document: bsx-20260729.htm0000885725-26-000051
Document: 0000885725-26-000051-index-headers.html0000885725-26-000051
Document: 0000885725-26-000051-index.html0000885725-26-000051
Document: 0000885725-26-000051.txt0000885725-26-000051
8-K Data (Synthetic)0000885725-26-000051

Track record

22 reports on BSX

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +9.24% at T+20 after the Aug 26, 2026 report. 6 of 8 went positive at some point.

Filters
  1. Oct 28, 202619d ago 8-K Bearish 6/10 No price data
  2. Oct 28, 202619d ago Press Release Bearish 5/10 Entry $42.43 Now $43.69 −2.97% settles Nov 25
  3. Oct 23, 202624d ago Institutional Cluster Bearish 4/10 Entry $45.69 Now $43.69 +4.38% settles Nov 20
  4. Oct 7, 20265w ago 8-K Mixed 6/10 Entry $41.58 to $45.82 Now $43.69 +5.07% ▲ +10.20% +11.54% vs SPY
  5. Sep 23, 20267w ago 8-K Bearish 5/10 Entry $44.62 to $44.51 Now $43.69 +2.08% ▲ +0.25% +0.93% vs SPY
  6. Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $48.08 to $43.65 Now $43.69 −9.13% ▼ −9.21% −9.57% vs SPY
  7. Aug 26, 202611w ago 8-K Bearish 6/10 Entry $48.17 to $43.72 Now $43.69 +9.30% ▲ +9.24% +10.44% vs SPY
  8. Aug 22, 202612w ago Institutional Cluster Mixed 6/10 Entry $49.01 to $44.92 Now $43.69 −10.85% ▼ −8.35% −9.66% vs SPY
  9. Aug 7, 202614w ago Insider Cluster Mixed 6/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
  10. Aug 7, 202614w ago Insider Cluster Mixed 5/10 Entry $50.46 to $44.98 Now $43.69 −13.42% ▼ −10.86% −9.95% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens Wed (10h 25m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026